Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies

April 7, 2019

Jeffrey A. Scott, MD, chief medical officer, Integra Connect, discusses how pharma can help community oncologists understand the value of novel and expensive therapies.

Jeffrey A. Scott, MD, chief medical officer, Integra Connect, discusses how pharma can help community oncologists understand the value of novel and expensive therapies.

Transcript

How can pharma be leveraged to help community oncologists better understand the value of novel and expensive therapies?

Back in the 80s and 90s, the value to the medical oncologist was the contract, the rebate, the discount. I think those days are going away. I think pharma’s role today in helping me is to support me with the use of real-world data, whether it’s clinical outcomes that occur once a drug is launched, or how does their drug compare in total cost of care versus another drug. Since I don’t always have the 2 new drugs compared head to head, I have to look at other sources of data. So, if I found out that one drug may use less growth factors and have less hospitalization, in the new world order of value-based care, that’s a big win. So, I think pharma needs to build the databases and the stories to support their drugs and the total picture of the care of the patient, not just on the drug side; how it impacts cost across that.